ライフサイエンスコーパス: adnexal

1 part reflects the high prevalence of benign adnexal abnormalities and the more frequent detection of

2 A lack of adnexal abnormalities on transvaginal sonography (negati

3 Excluded was ocular adnexal abnormality of any reason and incomplete tests.

4 Understanding of the ocular adnexal and intraocular lymphomas has advanced with prog

5 Adnexal and omental sections were independently scored b

6 The varied presentations of ocular adnexal and orbital amyloidosis often lead to a signific

7 In a post-hoc analysis, the Ovarian Adnexal and Reporting Data System (ORADS) at 10% was der

8 showed differential expression in epidermal, adnexal, and corneal epithelia but were not significantl

9 nical and histopathologic findings of ocular adnexal angiolymphoid hyperplasia with eosinophilia, an

10 Dermal sclerosis and adnexal atrophy are additional features of CR.

11 ejection, such as skin stricture, hair loss, adnexal atrophy, extensive fibrosis and mast cell infilt

12 Incidence was not increased for melanoma, adnexal carcinomas, and sarcomas.

13 spasm who were consecutively recruited from adnexal clinics at Moorfields Eye Hospital (January-June

14 Adnexal cyst characterization was determined by prospect

15 tients regarding the benign nature of simple adnexal cysts after a diagnostic-quality US examination

16 Background Ovarian and adnexal cysts are frequently encountered at US examinati

17 f malignancy in incidentally detected simple adnexal cysts at computed tomography (CT) to determine i

18 clusion The prevalence of previously unknown adnexal cysts at CT was 6.6%, with an ovarian cancer rat

19 rs and younger than 18 years with ovarian or adnexal cysts at least 2.5 cm were included.

20 dherence to SRU guidelines for management of adnexal cysts at our institution was 59%.

21 e interpreting radiologists' reports for 398 adnexal cysts detected at ultrasonography in 398 patient

22 etrospective review was performed, including adnexal cysts detected with ultrasonography (US) with su

23 e approach to asymptomatic ovarian and other adnexal cysts imaged at ultrasonography.

24 egarding the management of ovarian and other adnexal cysts imaged sonographically in asymptomatic wom

25 etween US and MRI for characterizing complex adnexal cysts measuring 5 cm or larger.

26 sts in Ultrasound (SRU) guidelines on simple adnexal cysts with recent large studies showing exceptio

27 ly low risk of cancer associated with simple adnexal cysts.

28 and December 2010 in women reported to have adnexal cysts.

29 ratification of symptomatic and asymptomatic adnexal cysts.

30 LMP tumors (12.8 pg/mL; P < .01) and benign adnexal disease (30.7 pg/mL; P < .01).

31 demonstrate that C. psittaci-negative ocular adnexal EMZL exhibit biased usage of IGHV families and g

32 Ocular adnexal EMZL shows frequent TNFAIP3 (A20) mutation/delet

33 in 67 Chlamydophila psittaci-negative ocular adnexal EMZL.

34 particularly around dermal blood vessels and adnexal epithelia.

35 nuckle skin was weak or absent, although its adnexal expression appeared normal and the punctate memb

36 an cancer developed subsequent to a negative adnexal finding at CT examination during a 15-44-month i

37 Patients with ocular adnexal follicular lymphoma primarily treated with EBRT

38 rent studies, WNV infected the epidermis and adnexal glands of mouse skin, and the epidermal cells we

39 The presence of adnexal hemorrhagic content was associated with nonviabl

40 nic mice reported here exhibit epidermal and adnexal hyperplasia, hyperkeratosis, and almost total al

41 Ocular adnexal IgG4 disease should especially be considered if

42 y and includes a diverse group of experts on adnexal imaging and management who developed the O-RADS

43 kelihood of cancer; and future directions of adnexal imaging for the early detection of ovarian cance

44 -solving tool through the use of the Ovarian-Adnexal Imaging Reporting and Data System (O-RADS) MRI l

45 Background The Ovarian-Adnexal Imaging Reporting and Data System (O-RADS) US ri

46 r reference to the evolving entity of ocular adnexal immunoglobulin G4 (IgG4) disease.

47 Adnexal injuries (eyelid lacerations and damage to lacri

48 Ocular or ocular adnexal injuries sustained from the Port of Beirut explo

49 Eighteen cases of ocular surface or ocular adnexal invasive squamous cell carcinomas were identifie

50 Bilateral ocular adnexal involvement (adjusted odds ratio [aOR] = 9.45; P

51 id hyperplasia with eosinophilia with ocular adnexal involvement are variable and include eyelid swel

52 Dacryoadenitis is the rarest form of ocular adnexal involvement in regional enteritis, which affects

53 quent ocular injuries include open-globe and adnexal lacerations.

54 f malignancy based on the MRI features of an adnexal lesion and provides information to facilitate op

55 ased clinical support system for ovarian and adnexal lesion assessment in women of average risk.

56 defined markedly hypointense foci within the adnexal lesion on T2-weighted images.

57 Women undergoing surgery for an adnexal lesion with solid tissue were included.

58 ients referred for surgery for an ovarian or adnexal lesion.

59 scoring system in a cohort of indeterminate adnexal lesions according to International Ovarian Tumor

60 ion systems to characterize US-indeterminate adnexal lesions and of the category-wise malignancy rate

61 odels can help nonexpert clinicians evaluate adnexal lesions and reduce surgical interventions for be

62 ic contrast-enhanced MRI scans to categorize adnexal lesions as benign or malignant and to evaluate t

63 mptoms who underwent surgery for ovarian and adnexal lesions before the O-RADS US risk score was publ

64 dy of women undergoing MRI for indeterminate adnexal lesions between March 2013 and March 2018, was q

65 Adnexal lesions can be stratified into the Ovarian-Adnex

66 roblem-solving modality in the evaluation of adnexal lesions depicted at US.

67 US risk stratification schemas for assessing adnexal lesions exist.

68 his article will review how the treatment of adnexal lesions has changed due to imaging over the deca

69 The fate of indeterminate adnexal lesions identified at unenhanced CT in 2869 cons

70 ore multifaceted than necessary for isolated adnexal lesions in average-risk women.

71 he inclusion of imaging in the evaluation of adnexal lesions in the 1970s, the rate of surgery for be

72 ole in differentiating benign from malignant adnexal lesions irrespective of lesion morphology.

73 rt of the standard of care for patients with adnexal lesions prior to definitive management.

74 Background US-indeterminate adnexal lesions remain an important indication for gynec

75 exal lesions, a non-negligible percentage of adnexal lesions remains indeterminate.

76 n schema of classic- or nonclassic-appearing adnexal lesions resulted in high sensitivity and specifi

77 MRI in differentiating benign from malignant adnexal lesions showing solid/mixed morphology.

78 Analysis of 1014 adnexal lesions using the O-RADS US risk stratification

79 Evaluation of adnexal lesions using the Simple Rules, ADNEX, and O-RAD

80 ) ages of patients with benign and malignant adnexal lesions were 44.1 (14.4) and 52.5 (15.2) years,

81 e, 52 years +/- 16 [SD]) with 262 ovarian or adnexal lesions were evaluated.

82 mean age, 53.2 years +/- 16.3 [SD]) with 372 adnexal lesions were included: 10 reports in the trainin

83 Incidental indeterminate adnexal lesions were relatively common at unenhanced CT

84 7 lesions) referred to MRI for evaluation of adnexal lesions were studied using 1.5 T MRI.

85 002, to July 24, 2012, 74 cystic hemorrhagic adnexal lesions with hyperintense signal on T1-weighted

86 e the proportion of patients with ovarian or adnexal lesions without acute symptoms who may have been

87 tudy parts from 12 studies (3731 women, 4520 adnexal lesions) met the inclusion criteria.

88 system for characterization of indeterminate adnexal lesions, a non-negligible percentage of adnexal

89 vides a standardized lexicon for ovarian and adnexal lesions, enables stratification of these lesions

90 atification of sonographically indeterminate adnexal lesions, partly based on time-intensity curve (T

91 In IOTA-SR indeterminate adnexal lesions, quantitative DWI significantly improves

92 s the initial modality for the assessment of adnexal lesions, while MRI is used when there is a clini

93 MRI systems to characterize US-indeterminate adnexal lesions, with pathologic examination and/or foll

94 isk assessment and management of ovarian and adnexal lesions.

95 ignant ovarian masses can present as complex adnexal lesions.

96 inction of benign from malignant ovarian and adnexal lesions.

97 for the characterization of US-indeterminate adnexal lesions.

98 s a problem-solving tool in the diagnosis of adnexal lesions.

99 ion of women referred for suspected or known adnexal lesions.

100 WI) in differentiating benign from malignant adnexal lesions.

101 This study included 913 women with 1014 adnexal lesions.

102 US can accurately help to characterize most adnexal lesions.

103 differentiating between benign and malignant adnexal lesions; this outcome has been previously report

104 s year, advances in the management of ocular adnexal lymphoid tumors have been based on the distincti

105 in patients with a prior diagnosis of ocular adnexal lymphoma (OAL) and to determine latency periods

106 efficacy of available treatments for ocular adnexal lymphoma (OAL) and to evaluate the outcomes and

107 features of the follicular subtype of ocular adnexal lymphoma (OAL) have not been previously evaluate

108 ge B-cell lymphoma (DLBCL) subtype of ocular adnexal lymphoma have not previously been evaluated in a

109 Patients with ocular adnexal lymphoma may benefit from regular surveillance t

110 Patients with prior diagnosis of ocular adnexal lymphoma possess increased risk of hematologic a

111 urrent systemic lymphoma (29.0%), and ocular adnexal lymphoma relapse of previous systemic lymphoma (

112 Of 1834 patients with primary ocular adnexal lymphoma, 279 developed a secondary malignancy d

113 ing for up to 80% of cases of primary ocular adnexal lymphoma, is marginal zone lymphoma of mucosa-as

114 ay be an alternative for treatment of ocular adnexal lymphoma.

115 xperience in 62 patients with primary ocular adnexal lymphomas (OALs).

116 Most ocular adnexal lymphomas are composed of neoplastic B-lymphocyt

117 n associated with the pathogenesis of ocular adnexal lymphomas in some parts of the world.

118 Lukes-Collins system for classifying ocular adnexal lymphomas.

119 database of 87,543 patients with ocular and adnexal malignancies.

120 ed in the management of patients with ocular adnexal MALT lymphoma, especially monoclonal antibody th

121 s have been adequately tested only in ocular adnexal MALT lymphomas where upfront doxycycline may be

122 present a state-of-the-art summary of ocular adnexal MALT lymphomas.

123 r knowledge, the clinical features of ocular adnexal mantle-cell lymphoma (OA-MCL) have not previousl

124 tween Chlamydophila psittaci (Cp) and ocular adnexal marginal zone lymphoma (OAMZL) and the efficacy

125 f the screening cohort, had an indeterminate adnexal mass (108 unilateral, 10 bilateral; mean size, 4

126 mination for the exploration of an equivocal adnexal mass (January 2007 to December 2012) with surgic

127 ness (LR+ 4.9; 95% CI, 1.7-14; n = 1435), an adnexal mass (LR+ 2.4; 95% CI, 1.6-3.7; n = 1378), and a

128 12) and control subjects either with benign adnexal mass (n = 5) or free from disease (n = 6).

129 onsecutive adult patients presenting with an adnexal mass between January 1, 2012, and March 1, 2015,

130 included 4905 patients with a newly detected adnexal mass in 17 centers that met predefined data qual

131 The presence of an adnexal mass in the absence of an intrauterine pregnancy

132 e selected for conservative management of an adnexal mass judged to be benign on ultrasound on the ba

133 arian torsion, MR imaging demonstrated right adnexal mass or inflammation.

134 nts aged 18 years or older with at least one adnexal mass who had been selected for surgery or conser

135 s of adnexal torsion in patients who have an adnexal mass with acute or subacute pelvic pain.

136 An adnexal mass with diffuse low-level internal echoes and

137 urgically in patients with a newly diagnosed adnexal mass.

138 118 women with malignant (60) or benign (58) adnexal mass.

139 Thirty-six patients with 50 adnexal masses (tubo-ovarian abscess, n = 24; ovarian ma

140 ith ovarian cancer are for the evaluation of adnexal masses and for the diagnosis and evaluation of r

141 an also be helpful in characterizing complex adnexal masses and in depicting recurrent tumor after tr

142 enign from malignant masses, the majority of adnexal masses are benign.

143 rian Tumor Analysis) Simple Rules classifies adnexal masses as benign, malignant, or indeterminate ba

144 B, persistent bleeding, or for evaluation of adnexal masses at the time of laparoscopy.

145 lded 54 patients with breast cancer and with adnexal masses at US and histopathologic examinations.

146 ive women with sonographically indeterminate adnexal masses between November 2016 and December 2018.

147 About 90% of adnexal masses can be adequately characterized with US a

148 nts, and supports conservative management of adnexal masses classified as benign by use of ultrasound

149 rospective studies on long-term follow-up of adnexal masses exist.

150 during the first 2 years of follow-up after adnexal masses have been classified as benign by use of

151 independently reviewed the sonograms of 252 adnexal masses in 226 women and recorded US features by

152 differentiating between benign and malignant adnexal masses is proportional to the expertise of the o

153 pian tubes and differentiate them from other adnexal masses on the basis of morphologic features.

154 All 11 patients with benign adnexal masses that clinically can be confused with mali

155 onsecutive patients aged 18 to 89 years with adnexal masses that were managed surgically or conservat

156 ctober 30, 2010, for characterization of 497 adnexal masses that were seen at US.

157 cale and Doppler sonographic features of 211 adnexal masses were correlated with the final diagnosis;

158 n in discriminating endometriomas from other adnexal masses were evaluated.

159 malignancy and acute complications is low if adnexal masses with benign ultrasound morphology are man

160 ging features that had been recorded for the adnexal masses with each imaging modality were reviewed

161 rospective study of sonographically detected adnexal masses with known clinical outcomes from two ins

162 Forty (74%) patients had benign adnexal masses, and 14 (26%) had malignant masses; three

163 ning risk of malignancy to ovarian and other adnexal masses, and to provide a management recommendati

164 set of 38 patients with surgically evaluated adnexal masses, but no hydrosalpinx, were randomly chose

165 more accurate and consistent evaluations of adnexal masses, especially when used by nonexpert clinic

166 lipid metabolic phenotypes in patients with adnexal masses, integrating quantitative lipidomics prof

167 n the evaluation of the pregnant patient for adnexal masses, pelvimetry, hydroureteronephrosis of pre

168 with the importance of careful reporting of adnexal masses, will also be reviewed.

169 nhanced MR imaging depicted 176 (94%) of 187 adnexal masses, with an overall accuracy for the diagnos

170 he detection and characterization of complex adnexal masses, with excellent inter- and intraobserver

171 ce to evaluate sonographically indeterminate adnexal masses.

172 a separate validation group of 39 women with adnexal masses.

173 lly or ultrasonographically detected complex adnexal masses.

174 (MRI), which revealed bilateral bulky solid adnexal masses.

175 MR imaging criteria for characterization of adnexal masses.

176 t frequently used to detect and characterize adnexal masses.

177 Fifty-five patients were included; ocular adnexal MCL was found to be most common in older individ

178 erentiated adenocarcinoma, nor did it affect adnexal metastasis.

179 While primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphom

180 Further, the development of ocular adnexal mucosa-associated lymphoid tissue lymphomas has

181 lator of NF-kappaB, were described in ocular adnexal MZL, suggesting a role for A20 as a tumor suppre

182 orders and whether it differs between ocular adnexal MZLs with (IgG4-associated MZL) and without (IgG

183 ion to the Gynecological Department excluded adnexal neoplasm.

184 ool database, 4.5% of feline intraocular and adnexal neoplasms (234/5153) were designated as feline o

185 dentified as potential aggravators of ocular adnexal neoplasms; however, given the rarity of these ne

186 erapy and radioimmunotherapy for orbital and adnexal non-Hodgkin's lymphoma and other lymphoprolifera

187 ary vitreoretinal lymphoma (PVRL) and ocular adnexal (OA)-uveal DLBCL.

188 s, duodenal ulcer, duodenitis, enteritis, or adnexal or testis pathologies.

189 The results demonstrate that the ocular and adnexal organs function as a unified visual system, with

190 ytomas, and cystadenomas of the reproductive adnexal organs.

191 , adrenal glands, pancreas, and reproductive adnexal organs.

192 interventions required to improve ocular and adnexal problems.

193 a relapse of systemic lymphoma in the ocular adnexal region.

194 rmation of epidermal, dermal, hypodermal and adnexal regulatory units.

195 phoma, and 10 (10%) presented with an ocular adnexal relapse.

196 assess interreader agreement of the Ovarian-Adnexal Reporting and Data System (O-RADS) and intermoda

197 Background The MRI Ovarian-Adnexal Reporting and Data System (O-RADS) enables risk

198 Background Ovarian-Adnexal Reporting and Data System (O-RADS) for MRI helps

199 The Ovarian-Adnexal Reporting and Data System (O-RADS) is an evidenc

200 The Ovarian-Adnexal Reporting and Data System (O-RADS) MRI Committee

201 sion Pelvic MRI interpreted with the Ovarian-Adnexal Reporting and Data System (O-RADS) MRI lexicon h

202 diffusion-weighted imaging (DWI) to Ovarian-Adnexal Reporting and Data System (O-RADS) MRI to improv

203 l lesions can be stratified into the Ovarian-Adnexal Reporting and Data System (O-RADS) risk of malig

204 More recently, data-driven Ovarian-Adnexal Reporting and Data System (O-RADS) scoring syste

205 American College of Radiology (ACR) Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound (U

206 First published in 2019, the Ovarian-Adnexal Reporting and Data System (O-RADS) US provides a

207 Background The Ovarian-Adnexal Reporting and Data System (O-RADS) US risk strat

208 The Ovarian-Adnexal Reporting and Data System (O-RADS) US risk strat

209 optimal diagnostic accuracy with the Ovarian-Adnexal Reporting and Data System MRI score.

210 rtiary referral oncology center, the Ovarian-Adnexal Reporting and Data System US risk stratification

211 This article reviews the Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging

212 that MMC is efficacious for treating ocular adnexal SC, albeit at the expense of LSC viability.

213 Ocular adnexal sebaceous carcinoma (OaSC) is an aggressive mali

214 acrimal gland and primary orbital and ocular adnexal soft tissue tumors; reappraisal of diagnostic, p

215 s to update ophthalmologists and orbital and adnexal specialists with the emerging role of targeted m

216 ic-pathologic correlation was performed with adnexal specimens imaged in vitro in three study patient

217 other organs, just the aging of skin and its adnexal structure the hair follicle can result in cosmet

218 Skin has disadvantages of adnexal structures and a different keratinization patter

219 s residing close to the surface and includes adnexal structures and present data showing that tape an

220 ncreased complexity that better mimic native adnexal structures can have a substantial impact on rege

221 on also restored skin architecture including adnexal structures in ear wounds and dermal-epidermal ju

222 on to keratinocytes and keratinocyte-derived adnexal structures in the skin.

223 Overlap with ocular adnexal structures is common, and ancillary imaging is e

224 was associated with atrophy of epidermal and adnexal structures of skin; a similar phenotype is repor

225 gment our PS-OCT measurements by visualizing adnexal structures such as hair follicles to relay overa

226 roaches fail to adequately introduce complex adnexal structures such as hair follicles within tissue

227 Other ocular adnexal structures were affected in 13 patients (59.1%),

228 Initial development of the skin's epidermis, adnexal structures, and barrier function is necessary fo

229 ervation of normal histology of the skin and adnexal structures.

230 were characterized in the rat eye and ocular adnexal structures.

231 unction and more compact dermis with loss of adnexal structures.

232 ss (LR+ 2.4; 95% CI, 1.6-3.7; n = 1378), and adnexal tenderness (LR+ 1.9; 95% CI, 1.0-3.5; n = 1435)

233 Expert consensus on ocular and adnexal terms.

234 r diseases that involve the orbit and ocular adnexal tissue, such as lymphoma, hemangioma, sarcoidosi

235 is a rare disease that can affect the ocular adnexal tissue.

236 s an accurate technique for the diagnosis of adnexal torsion in patients who have an adnexal mass wit

237 Features associated with adnexal torsion were identified by using univariate and

238 l: 1.2, 56.8], P = .03) were associated with adnexal torsion, with substantial interreader agreement

239 Twenty-two patients (38%) had a diagnosis of adnexal torsion.

240 sts who had managed, on average, 52 globe or adnexal trauma cases throughout their careers and/or pub

241 their membership in ophthalmology (globe and adnexal trauma) societies.

242 d/or published a total of 5 or more globe or adnexal trauma-related peer-reviewed articles.

243 onths, 34 (28%) patients developed no ocular/adnexal tumor, 86 (72%) developed ocular surface maligna

244 itted to our hospital with suspicion of left adnexal tumor.

245 erred to our hospital with suspicion of left adnexal tumor.

246 udy investigates the role of TKTL1 in ocular adnexal tumors and analyzes how its expression correlate

247 Thus, we reveal the genomic landscape of adnexal tumors and therapeutic targets.

248 ognostic, and therapeutic approach to ocular adnexal tumors in light of emerging molecular genetic da

249 of epithelial tumors, particularly cutaneous adnexal tumors that are rare in mice.

250 radenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and pote

251 tion of PD-L1 and PD-L2 expression in ocular adnexal tumors.

252 a condition characterized by numerous benign adnexal tumors.

253 pological and functional differences between adnexal tumours and distal peritoneal foci.

254 7, 2004, and April 23, 2006, with suspected adnexal tumours met the inclusion criteria.

255 d anti-Yo antibody response in whom ovarian, adnexal, uterine, or breast cancer cannot be detected.